at the ER, indicating a perturbation of protein secretion. In conclusion, by interference with V-ATPase, archazolid significantly affects the secretion of cytokines due to accumulation at the ER which might be of relevance when using these agents for cancer therapy.
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Introduction
Monocytes are a major component of innate immunity that traffic via the bloodstream to peripheral tissues and upon recruitment protect the host against pathogenic microorganisms [1] . However, recruited monocytes also contribute to the pathogenesis of inflammatory and degenerative diseases, including cancer. For example, monocytes can infiltrate the tumor microenvironment and support the persistence of an inflammatory milieu (e.g., by production of cytokines) and thus, contribute to all phases of the cancer progression [2, 3] . In particular, the pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8 produced by activated and infiltrating monocytes are key players of inflammatory disorders and also promote tumor development [4, 5] . Thus, anti-inflammatory drugs represent valid complementary strategies also for cancer prevention and therapy [2] . Recent studies suggest that the combination of direct cytotoxic activity on tumor cells with a capacity to favorably modify the inflammatory tumor microenvironment is an appealing option for treatment of diverse cancers with clinical relevance [6] , as shown for the natural compound trabectedin [7] . However, the identification of novel and relevant targets is currently required in order to simultaneously hit viability of neoplastic cells and inflammation in immune cells by a single agent.
The vacuolar-type H(+)-ATPases (V-ATPases) are ATP-dependent proton translocating macromolecular complexes that acidify lysosomes, endosomes, Golgi apparatus, and certain secretory granules in all eukaryotes [8] . V-ATPases participate in physiological processes such as receptor-mediated endocytosis, intracellular trafficking, protein degradation and processing, but they are also implicated in several diseases including osteoporosis, renal tubular acidosis, and malignant neoplasms [9] . In cancer, V-ATPase is highly expressed on the plasma membrane of tumor cells and particularly contributes to the acidification of tumor microenvironments, thus supporting tissue damage, the acquisition of metastatic cell phenotypes and tumor invasiveness [10] . Accordingly, specific inhibitors of V-ATPases decreased the acidity of tumors, reduced 5 survival of tumor cells and tumor metastasis, and impaired chemoresistance [11, 12] . Therefore, VATPase is considered as promising target in various types of cancer, but whether it may simultaneously regulate relevant inflammatory pathways in primary human monocytes is unknown.
Here, we made use of the natural V-ATPase inhibitor archazolid to analyze whether and how the release of pro-inflammatory cytokines related to tumor-promoting inflammation is regulated by VATPase in primary monocytes from healthy humans. In fact, archazolids bind to V-ATPase [13, 14] and recent work has shown that archazolid induced apoptosis and reduced migration of invasive tumor cells, decreased metastatic dissemination of breast tumors and spatially restricted activation of EGFR and Rho-GTPase Rac1 in vivo [15] . In various highly invasive tumor cell lines, archazolid led to apoptosis due to activation of the hypoxia-inducible factor-1α (HIF1α), autophagy [16] , and anoikis induction [17] . Thus, archazolid currently represents a promising candidate for direct targeting of tumor cells via V-ATPase inhibition, but the analysis of its effects on inflammation is required for a comprehensive understanding of the therapeutic potential of V-ATPase inhibition.
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Materials and Methods
Materials
Archazolid B was isolated from Archangium gephyra as described [18] . Apicularen A was obtained from the natural compound library of HZI/HIPS (Braunschweig, Germany). RPMI 1640 medium with L-glutamine, penicillin, streptomycin, and human serum were from PAA Laboratories (Pasching, Germany). For in-house made ELISA, the capture and detection antibodies were from R&D Systems (Abington, UK). U0126 and SP600125 were from Enzo Life Sciences (Lörrach, Germany) and staurosporine from Calbiochem (Merck, Darmstadt, Germany). Bafilomycin, dexamethasone, cycloheximide (CHX) and all other fine chemicals were from Sigma-Aldrich (Steinheim, Germany), unless indicated otherwise.
Isolation of blood cells and Mono Mac 6 cell culture
Leukocyte concentrates, prepared from freshly withdrawn peripheral blood of healthy adult human donors who had not taken any anti-inflammatory drugs for the last 10 days, with consent, were obtained from the Institute of Transfusion Medicine at University Hospital Jena, Germany. Platelets and peripheral blood mononuclear cells (PBMC) were isolated by dextran sedimentation and centrifugation on LSM 1077 lymphocyte separation medium (PAA Laboratories, Pasching, Germany), as described [19, 20] . To obtain monocytes, PBMC were collected, washed two times with cold PBS, and monocytes were separated by adherence for 1.5 h at 37 °C to culture flasks (210 7 cells/mL RPMI 1640 medium containing 2 mM L-glutamine and 100 U/mL penicillin plus 100 µg/mL streptomycin). Monocytes were finally resuspended in PBS, with a purity of >85%, defined by forward-and side-light scatter properties and detection of the CD14 surface molecule by flow cytometry (BD FACS Calibur, Heidelberg, Germany).
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The human monocytic MM6 cell line (kindly provided by Dr. Thorsten Maier, University of Frankfurt, Germany) was cultured in RPMI 1640 medium, supplemented with heat-inactivated fetal calf serum (FCS, 10%, v/v), 100 U/mL penicillin, 100 µg/mL streptomycin, 10 µg/mL insulin, 1 mM oxaloacetic acid, 1 mM sodium pyruvate and 1non-essential amino acids at 37 °C and 5% CO2.
Determination of cell viability
Cell viability was assessed by MTT assay as described [21] . Briefly, monocytes were preincubated (30 min, 37 °C, 5% CO2) with compounds and stimulated with 10 ng/mL LPS or left untreated for the indicated times. MTT was added, cells were further incubated for 2 h, and lysed in a buffer containing 10% (w/v) SDS. Staurosporine, an inducer of apoptosis, was used as positive control. Monocytes were incubated in RPMI 1640 medium plus 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine without serum overnight for starvation. Cells were preincubated with compounds or DMSO (30 min, 37 °C), 2% human serum was added and cells were stimulated with LPS (100 ng/mL) for 5 min (p38 MAPK, ERK-1/2, Akt, SAPK/JNK) or 15 min (IκB). For analysis of BiP expression, monocytes were plated in monocyte medium, pre-incubated with compounds or DMSO (30 min, 37 °C) and stimulated with LPS (1 µg/ml) for 24 h. Cells were placed on ice, washed twice with PBS and lysed by NP-40 (1%) as described [19] . Lysates were centrifuged (10,000g, 4 °C, 5 min), and protein concentrations in the supernatants were 
Subcellular fractionation
For cell fractionation experiments, 310 µl ice-cold TKM buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose, 25 mM KCl, 5 mM MgCl2, 1 mM EDTA, 60 µg/mL soybean trypsin inhibitor, 1 mM phenylmethylsulfonyl fluoride and 10 µg/mL leupeptin), and sonicated (10 strokes, lowest intensity) on ice. Cell debris was spun down (600g, 10 min, 4 °C), and supernatants were mixed with 4SDS loading buffer and boiled for 5 min. To separate ER-and Golgi-containing cellular fractions, the supernatants after 600×g centrifugation were spun at 13 000×g (10 min, 4 °C). The pellet (P13) containing the ER [22] , was again resuspended in 200 µl TKM buffer, sonicated on ice and boiled after 4SDS loading buffer addition. The supernatant (S13) was centrifuged at 100 000×g (1.5 h, 4 °C). The resulting pellet (P100, containing Golgi) was also resuspended in 200 µl TKM buffer and sonicated on ice. Both, P100 and the supernatant (S100) were mixed with 4SDS loading buffer and boiled for 5 min.
SDS-PAGE and Western-Blot were performed as described above. Antibodies against the c-subunit of V-ATPase (1:1000 anti-ductin, Biozol, Eching, Germany), Calnexin (1:1000, Merck, Darmstadt, Germany), GM130 (1:1000, BD Biosciences, Heidelberg, Germany), LAMP1 (1:1000, Abcam, Cambridge, UK), β-actin and β-tubulin (1:1000, Cell Signaling Technology, MA, USA) were used.
Bands were visualized and band intensities were quantified (after background correction) using the Odyssey imaging system (LI-COR Biosciences, Bad Homburg, Germany).
Determination of intracellular and extracellular cytokine levels
Monocytes (1.5×10 6 /mL) were resuspended in monocyte medium (RPMI 1640 containing 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 2% (v/v) human serum). After 
Immunofluorescence microscopy
/ml) were seeded on glass coverslips and incubated for 1.5 h at 37 °C at 5% CO2.
After monocyte attachment, residual cells were removed by washing with PBS. Monocytes were pre-incubated with test compounds (30 min) and then stimulated with LPS (10 ng/mL) for 4 h at 37 °C and 5% CO2. Cells were fixed with 4% formaldehyde solution in PBS, free formaldehyde was 
Relative quantification of IL-8 RNA expression in monocytes
Monocytes (1.510 6 /mL) were preincubated with archazolid (10 nM) or DMSO for 30 min and stimulated with 10 ng/mL LPS for indicated times or left untreated at 37 °C and 5% CO2. Total RNA from monocytes was isolated by guanidinium thiocyanate/phenol/chloroform extraction as described [23] . cDNA was generated by reverse transcription. The cDNA was amplified by PCR and quantified using the MyiQ Singl-Color Real-Time PCR Detection System (Bio-Rad Laboratories, Munich, Germany). To calculate the relative IL-8 mRNA expression (normalized to GAPDH) the 2 (ΔΔC(T)) method was used (23 
Analysis of vesicular & cytosolic pH in monocytes
The pH measurements were performed as reported [24] and compositions of sodium and potassium buffers were used as described [25] . For measurements of cytosolic pH, monocytes (1. min and red fluorescence of the accumulated probe in acidic cell organelles was imaged using the Axio Observer Z1 microscope.
Statistics
The data are presented as mean SEM of n experiments. Statistical analysis was performed by one-way ANOVA for independent or correlated samples followed by Bonferroni post hoc test or by Student t test [26] . Data were analyzed with GraphPad InStat program (GraphPad Software, CA). A P value of < 0.05 was considered significant.
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Results
Monocytes express V-ATPase and respond to V-ATPase inhibition by archazolid without loss of cell viability
In order to ensure that primary human monocytes can respond to archazolid via V-ATPase, we first analyzed the occurrence of the V-ATPase protein in these cells. V-ATPase protein (c subunit) was detected in total cell lysates of primary PBMC and monocytes from human peripheral blood, whereas in platelets for instance, V-ATPase was essentially absent (Fig. 1A) . However, the amount of V-ATPase in primary monocytes was lower versus transformed monocytic MM6 cells. After high-speed centrifugation (100 000×g) of the monocyte lysates, V-ATPase protein was essentially in the pelletable fraction (Fig. 1A) . After differential centrifugation at 13 000×g and 100 000×g, VATPase was found in the pellet of the 13 000×g (P13) but not in the pellet (P100) after 100 000×g centrifugation, thus co-sedimenting with markers of ER and lysosomal vesicles (i.e., calnexin and LAMP1, respectively), but not with the Golgi marker GM130; no significant amounts of V-ATPase protein was detected in the supernatants (S100) (Fig. 1C) .
Next, we investigated whether archazolid functionally interferes with V-ATPase in monocytes and thus, elevates the vesicular pH by blocking V-ATPase-dependent proton transport into vesicles.
Two methods were applied: (I) fluorescence microscopy using the Lysotracker probe which stains acidic compartments, and (II) fluorescence measurement of internalized FITC-dextran, which is pH-dependent. The results show that within 4 h, 10 nM archazolid causes a slight, and at 100 nM archazolid a significant increase of the pH of otherwise acidic cell organelles ( Fig. 2A, B) . These effects occurred in a concentration-dependent manner and were observed also for the structurally unrelated V-ATPase inhibitor apicularen (10 and 100 nM) (Fig. 2B) . Note that the cytosolic pH of archazolid-treated monocytes (10 or 100 nM arachzolid) was instead not increased but slightly decreased, as expected (Fig. 2B) .
As an increase of the vesicular pH by V-ATPase inhibitors is proposed to cause cancer cell death
[10], we analyzed monocyte viability after archazolid treatment using the MTT assay. Of interest, archazolid up to 1000 nM failed to induce significant monocyte death within 24 h, whereas staurosporine (3 µM, used as positive control) caused almost complete loss of cell viability (Fig.   2C) . Also, the V-ATPase inhibitor apicularen (10-1000 nM) was not cytotoxic for monocytes (Fig.   2C ). Together, primary monocytes express functional V-ATPase, and inhibitors of V-ATPase increase the vesicular pH, but in contrast to cancers cells, V-ATPase inhibitors cause no loss of viability.
Archazolid modulates cytokine release in activated monocytes without affecting related protein kinase signaling
We next investigated if archazolid alters the release of inflammation-related cytokines in monocytes. In agreement with the literature [27] , LPS caused release of the pro-inflammatory TNF-α, IL-1β, IL-6 and IL-8 and the anti-inflammatory IL-10 from primary monocytes (Fig. 3) .
Pretreatment with archazolid impaired LPS-induced release of TNF-α, IL-6, and IL-10 with effective concentrations in the range of 1 -10 nM (reaching a plateau at higher concentrations) and similar efficiency as the anti-inflammatory compound dexamethasone (1 µM) (Fig. 3A) . Of interest, archazolid markedly suppressed IL-8 release, which was instead not affected by dexamethasone, and similar effects on IL-8 were observed for the V-ATPase inhibitors apicularen and bafilomycin (Fig. 3A,B) . The protein synthesis inhibitor cycloheximide (CHX, 5 µM) caused a comparable effect as the V-ATPase inhibitors. Intriguingly, archazolid promoted the LPS-induced release of IL-1β, which was significant at 10 and 100 nM, whereas dexamethasone suppressed IL-1β liberation
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( Fig. 3C) . Also bafilomycin and apicularen showed a tendency to increase LPS-induced IL-1β release (Fig. 3C) .
We next investigated the phosphorylation of signaling molecules involved in LPS-induced cytokine expression, such as p38 MAPK, Akt, ERK-1/2, SAPK/JNK, and IκBα [27] , which might be repressed by archazolid concomitantly with impaired cytokine release. However, the LPS-induced phosphorylation of these proteins was not diminished by archazolid (Fig. 3D) , suggesting that LPS signaling down to the recruitment of relevant transcription factors (e.g., NF-κB) is not targeted by V-ATPase inhibition.
Inhibition of V-ATPase by archazolid causes intracellular accumulation of IL-8 in activated monocytes
We aimed to mechanistically analyze the effect of archazolid on pro-inflammatory cytokines and (Fig. 4B) . However, co-incubation with archazolid (1 to 10 nM) reduced the amount of secreted IL-8 but concomitantly increased the intracellular portion. A similar effect was observed when TNF-α was analyzed (not shown). The same pattern was observed for apicularen and bafilomycin (10 nM, each), whereas CHX impaired in contrast both extra-and intracellular IL-8 levels, as expected (Fig. 4B) .
V-ATPase inhibition by archazolid may block secretion of de-novo synthesized IL-8, presumably
by increasing the pH in the secretory pathway. We thus investigated the extra-and intracellular IL-8 distribution pattern of LPS-stimulated monocytes in the presence of suitable tool compounds.
Brefeldin A (BFA) that inhibits secretion by fusing the Golgi and the ER [28] also led to accumulation of intracellular IL-8 and impaired extracellular release, as expected (Fig. 4C) .
Similarly, the Na + /H + antiporter monensin that blocks intracellular protein transport [29] , led to an IL-8 distribution pattern as found for archazolid, that is, elevated IL-8 protein in the cell but reduced levels in the extracellular space (Fig. 4C) .
Next, we confirmed archazolid-mediated intracellular IL-8 accumulation in monocytes by IF microscopy. In unstimulated and LPS-treated monocytes, IL-8 (green staining) localized to a compact structure, presumably the Golgi-area, partially "encircled" by the kidney bean-shaped nucleus (DAPI-stained, blue). Such a staining is typical for a secreted protein and was also observed for TNF-α (not shown). This IL-8 distribution pattern was essentially not altered for cells treated with CHX (Fig. 4D) . However, archazolid caused a massive enrichment of IL-8 (and of TNF-α, not shown) within the entire non-nuclear environment, in addition to the juxtanuclear, compact structure. A similar pattern was observed for monensin-treated monocytes, whereas BFA caused rather homogenous distribution of IL-8 without marked accumulation in the Golgi-area, consistent with the disassembly of the Golgi caused by BFA (Fig. 4D) .
Correlation between increased vesicular pH and intracellular accumulation of IL-8
We speculated that the intracellular IL-8 accumulation is caused by an increase of the vesicular pH after archazolid treatment. Therefore, we compared the effects of archazolid on vesicular pH and IL-8 secretion with those of NH4Cl and chloroquine that are known to elevate the pH of cell organelles. NH4Cl seemingly increased the vesicular pH (Fig. 5A) in LPS-stimulated monocytes, and in parallel retained LPS-induced IL-8 protein in the cell at the expense of released IL-8 ( Fig.   5B) , a pattern observed also for archazolid. Also 100 µM chloroquine also slightly elevated the vesicular pH, but in contrast to archazolid and NH4Cl, only the extracellular IL-8 was diminished without concomitant IL-8 accumulation in the cell.
Archazolid B causes accumulation of IL-8 at the ER and induces ER stress response
Using selective marker proteins of subcellular compartments/organelles related to classical protein secretion from ER via the Golgi into the extracellular space (Fig. 6A) , we tested where IL-8
accumulates upon archazolid treatment. For visualization of the Golgi-area we used TGN38 and giantin, marking the trans-Golgi network or the cis-and medial-Golgi, respectively. Both stained the compact structure encircled by the bean-shaped nucleus and colocalized with IL-8, confirming
that IL-8 is enriched in the Golgi-area (Fig. 6B) . Both markers did not co-localize with the (Fig. 6C) .
To confirm IL-8 accumulation at the ER by archazolid, we investigated the occurrence of ER stress (which failed to increase IL-8 at the ER) caused no elevation of BiP (Fig. 6D) .
Discussion
Here we showed that archazolid represses the secretion of TNF-α, IL-6, IL-8, and IL-10 in LPSstimulated primary human monocytes at effective concentrations of 10 nM. Our data indicate that archazolid causes retention of de-novo synthesized IL-8 (and TNF-α) at the ER associated with ER stress by inhibition of V-ATPase, without blocking IL-8 mRNA or protein expression. Comparative studies with apicularen and bafilomycin [30] imply that repression of cytokine release in activated monocytes is a class effect of V-ATPase inhibitors. Notably, central signaling pathways (i.e., p38
MAPK, Akt, ERK-1/2, SAPK/JNK, and IκB) involved in LPS-induced monocyte activation, cytokine expression and secretion, as well as monocyte viability were unaffected by archazolid, indicating that the anti-inflammatory effect was achieved without a general cellular perturbation and V-ATPase inhibition was not leading to cytotoxicity in monocytes.
In contrast to monocytes, archazolid in vitro is instead well-documented to induce cell death in different cancer cells [15, 16, 18, 31] and its anti-tumoral activity in vivo has recently been reported [15, 32] The occurrence of V-ATPase in monocytic cells was demonstrated before [35] , but the focus of VATPase research was placed on leukemia-derived cells lines (e.g., THP-1 and U937) [36] and on other differentiated cells of the monocyte/macrophage haematopoietic lineage including osteoclasts [37] . In fact, V-ATPase expression is increased during macrophage differentiation of THP-1 and U-937 [36] . We find that primary monocytes express membrane-associated V-ATPase that upon differential centrifugation co-localized with markers of the ER (calnexin) and lysosomes (LAMP1) but not with the Golgi (marker GM130). Also in our hands, V-ATPase protein was more abundant in the monocytic leukemia-derived cell line MM6 as compared to primary monocytes, supporting the hypothesis that hyperproliferative cells overexpress V-ATPase to maintain malignant growth [11, 12] . Despite lower protein levels, however, V-ATPase is expressed as functionally active enzyme in primary monocytes and archazolid or apicularen increased the vesicular pH. Similarly, in monocytic U937 cells, intracellular pH regulation by V-ATPase was shown by using bafilomycin as V-ATPase blocker [38] .
Release of various cytokines is a major function of activated monocytes [1] and members of these secreted pro-inflammatory proteins, including TNF-α, IL-6 and IL-8, are key players in inflammation-triggered cancer [4, 5] . Archazolid caused suppression of LPS-induced TNF-α, IL-6, IL-8, and IL-10 release with significant effects at 10 nM. Note that the effectiveness of archazolid to repress TNF-α and IL-6 was limited to about 50% but still comparable to the effect of high dose
(1 µM) dexamethasone, used as control [39] . Apicularen and bafilomycin caused similar effects as archazolid suggesting a class effect of V-ATPase inhibitors. Also, IL-10 release was more efficiently blocked by archazolid as compared to dexamethasone. On the other hand, the LPSinduced release of IL-1β was not inhibited but instead was enhanced by archazolid as well as by 21 apicularen and bafilomycin, while dexamethasone efficiently reduced its secretion, as reported [40] .
IL-1β possesses multiple and diverse properties in response to infections, injury, immune challenge, and it eventually ensures the recovery from trauma or infections, but also plays a pathogenic role in many chronic diseases, including diabetes, atherosclerosis and cancer [41] . Thus, an elevated IL-1β release should be considered in this respect when applying V-ATPase inhibitor in vivo.
Interestingly, IL-1β lacks a secretory signal sequence and is, unlike TNF-α, IL-6, IL-8, and IL-10, secreted by alternative routes (not blocked by BFA or monensin) than the classical ER-Golgi pathway [42] . IL-1β secretion may involve the externalization of the cytokine directly at the plasma membrane, via vesicles or microvesicles shed from the plasma membrane, and also exosomes may carry IL-1β out of the cell [42] . Together, archazolid and dexamethasone seem to modulate different signaling pathways. In fact, archazolid failed to affect transcription of IL-8 in LPSactivated monocytes, in contrast to dexamethasone [43] .
We found that the impaired extracellular release of IL-8 and TNF-α by V-ATPase inhibitors was accompanied by intracellular enrichment. BFA that inhibits secretion and fuses ER and Golgi [28, 44] also led to accumulation of intracellular IL-8 along with impaired amounts of released IL-8, and a similar effect was observed with the Na + /H + antiporter monensin that blocks protein transport in the Golgi [29] . On the other hand, CHX that inhibits de-novo protein biosynthesis by blocking translational elongation [45] impaired the amounts of both extra-and intracellular IL-8.
Conclusively, the reduced IL-8 release in LPS-stimulated monocytes by archazolid or apicularen was apparently due to a blockade of the secretion of de-novo synthesized IL-8 protein.
Bafilomycin impaired the transport between early and late endosomes by inhibiting acidification through V-ATPase inhibition [46] . Using NH4Cl as tool compound to increase the pH in the secretory pathway, our data correlate organellar alkalization to repression of IL-8 release and intracellular accumulation of IL-8, respectively. Chloroquine only slightly increased the pH in secretory organelles, IL-8 was not enriched in the cell, and BiP expression was not enhanced though extracellular IL-8 levels were lowered. This suggests that chloroquine affects expression of IL-8, supported by the finding that in LPS-stimulated monocytes chloroquine decreases IL-1β and IL-6 mRNA and blocks maturation of TNF-α protein rather than blocking their secretion [47, 48] .
Most cytokines including TNF-α, IL-6, IL-8, and IL-10 are released through classical secretion [49] . Thus, after cotranslational translocation into the ER, the cytokines are collected at the ERES, transported to the ERGIC from there through the Golgi to the TGN, where they are packaged in secretory vesicles and exocytosed through the plasma membrane (see Figure 6A) . A recent study (C) Protein analysis in subcellular fractions of primary human monocytes. Whole cell lysates of primary human monocytes were centrifuged at 13 000g yielding pellet (P13) and supernatant (S13). The S13 was further centrifuged at 100 000g leading to supernatant (S100) and pellet 
